SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-059374
Filing Date
2021-12-06
Accepted
2021-12-06 08:00:47
Documents
14
Period of Report
2021-12-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K ktra-8k_20211203.htm   iXBRL 8-K 43428
2 GRAPHIC gypnebpcvbcs000002.jpg GRAPHIC 5293
3 GRAPHIC gypnebpcvbcs000001.jpg GRAPHIC 5293
  Complete submission text file 0001564590-21-059374.txt   188642

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ktra-20211203.xsd EX-101.SCH 5681
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ktra-20211203_lab.xml EX-101.LAB 19335
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ktra-20211203_pre.xml EX-101.PRE 11483
7 EXTRACTED XBRL INSTANCE DOCUMENT ktra-8k_20211203_htm.xml XML 3527
Mailing Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130
Business Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 211472031
SIC: 2834 Pharmaceutical Preparations